Lannett Launches Authorized Tirosint In US
Company Expects To Be ‘One Of Two Suppliers’ Of Generic Tirosint
Lannett has launched levothyroxine sodium capsules, an authorized generic version of Tirosint, in partnership with IBSA in the US. The company faces the possibility of competition, as Teva may enter the market with certain generic strengths.
You may also be interested in...
With a mission to provide access “to high quality, affordable, authorized generics and complex generic medicines to enhance healthcare outcomes,” Yaral Pharma has launched in the US.
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Lannett enters into an agreement with Cediprof for an exclusive 10-year future supply and distribution agreement of levothyroxine starting 1 August 2022.